Smith & Nephew SNATS Inc (SNN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Smith & Nephew SNATS Inc stock (SNN) is currently trading at $32.45. Smith & Nephew SNATS Inc PE ratio is 22.49. Smith & Nephew SNATS Inc PS ratio (Price-to-Sales) is 2.21. Analyst consensus price target for SNN is $36.62. WallStSmart rates SNN as Hold.
- SNN PE ratio analysis and historical PE chart
- SNN PS ratio (Price-to-Sales) history and trend
- SNN intrinsic value — DCF, Graham Number, EPV models
- SNN stock price prediction 2025 2026 2027 2028 2029 2030
- SNN fair value vs current price
- SNN insider transactions and insider buying
- Is SNN undervalued or overvalued?
- Smith & Nephew SNATS Inc financial analysis — revenue, earnings, cash flow
- SNN Piotroski F-Score and Altman Z-Score
- SNN analyst price target and Smart Rating
Smith & Nephew SNATS Inc
📊 No data available
Try selecting a different time range
SNN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Smith & Nephew SNATS Inc (SNN)
SNN trades at a significant discount to its Graham intrinsic value of $66.92, offering a 47% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Smith & Nephew SNATS Inc (SNN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, eps growth. Concerns around institutional own.. Fundamentals are solid but monitor weak areas for improvement.
Smith & Nephew SNATS Inc (SNN) Key Strengths (3)
Growing significantly faster than its price suggests
Earnings per share surging 70.40% year-over-year
Large-cap company with substantial market presence
Supporting Valuation Data
Smith & Nephew SNATS Inc (SNN) Areas to Watch (7)
Very low institutional interest at 7.67%
Thin operating margins with cost pressures present
Modest revenue growth at 7.40%
Moderate profitability with room for improvement
Revenue is fairly priced at 2.21x sales
Fairly priced relative to book value
Decent profitability, keeps $10 per $100 revenue
Smith & Nephew SNATS Inc (SNN) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.7/10) while 7 fall into concern territory (avg 4.7/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, EPS Growth, Market Cap. Valuation metrics including PEG Ratio (0.66) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 70.40%.
The Bear Case
The primary concerns are Institutional Own., Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.21), Price/Book (2.58) suggest expensive pricing. Growth concerns include Revenue Growth at 7.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 11.80%, Operating Margin at 14.00%, Profit Margin at 10.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, EPS Growth) and negatives (Institutional Own., Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SNN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SNN's Price-to-Sales ratio of 2.21x sits near its historical average of 2.35x (17th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 16% below its historical high of 2.63x set in Mar 2026, and 1% above its historical low of 2.2x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Smith & Nephew SNATS Inc (SNN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Smith & Nephew SNATS Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 6.2B with 7% growth year-over-year. Profit margins of 10.1% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 595M in free cash flow and 888M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Smith & Nephew SNATS Inc push profit margins above 15% as the business scales?
Debt management: total debt of 3.5B is significantly higher than cash (675M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Smith & Nephew SNATS Inc.
Bottom Line
Smith & Nephew SNATS Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Smith & Nephew SNATS Inc(SNN)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.